A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus.
A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus.
复制标题
DOI：
10.1371/journal.pone.0107986
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Gan J
中科院分区：
文献类型：
--
作者：
Tan Y;Ge G;Pan T;Wen D;Chen L;Yu X;Zhou X;Gan J
识别新的高灵敏度和高特异性的肝癌标志物是必不可少的。我们的目的是确定血清microRNAs（miRNAs）作为诊断B型肝炎病毒（HBV）相关肝细胞癌（HCC）的生物标志物。我们研究了2010年8月至2013年6月期间招募的261名HCC患者，233名肝硬化患者和173名健康对照者的血清miRNA表达。使用从HCC患者和对照合并的血清样品通过Illumina测序进行miRNA表达的初始筛选。使用定量逆转录聚合酶链反应（qRT-PCR）来评估所选miRNA的表达。使用训练队列（n = 357）构建逻辑回归模型，然后使用独立队列（n = 241）进行验证。 使用受试者工作特征曲线下面积（AUC）来评价使用生物标志物进行疾病诊断的准确性。我们鉴定了8种miRNA（hsa-miR-206、hsa-miR-141- 3 p、hsa-miR-433- 3 p、hsa-miR-1228- 5 p、hsa-miR-199 a-5 p、hsa-miR-122- 5 p、hsa-miR-192- 5 p和hsa-miR-26 a-5 p），并构建了一个miRNA集，其提供了HCC的高诊断准确性（训练集和验证集的AUC分别为0.887和0.879）。 miRNA也可用于区分HCC患者与健康（AUC = 0.893）和肝硬化（AUC = 0.892）患者。 我们鉴定了一组在HCC诊断中具有相当临床价值的血清miRNA。
The identification of new high-sensitivity and high-specificity markers for HCC are essential. We aimed to identify serum microRNAs (miRNAs) as biomarkers to be used in diagnosing hepatitis B virus (HBV) –related hepatocellular carcinoma (HCC). We investigated serum miRNA expression in (261 HCC patients, 233 cirrhosis patients, and 173 healthy controls), recruited between August 2010 and June 2013. An initial screening of miRNA expression by Illumina sequencing was performed using serum samples pooled from HCC patients and controls. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) was used to evaluate the expression of selected miRNAs. A logistic regression model was constructed using a training cohort (n = 357) and then validated using an independent cohort (n = 241). The area under the receiver operating characteristic curve (AUC) was used to evaluate the accuracy of the use of the biomarkers for disease diagnosis. We identified 8 miRNAs (hsa-miR-206, hsa-miR-141-3p, hsa-miR-433-3p, hsa-miR-1228-5p, hsa-miR-199a-5p, hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-26a-5p) and constructed an miRNA set that provided high diagnostic accuracy for HCC (AUC = 0.887 and 0.879 for training and validation sets, respectively). The miRNAs could also be used to differentiate HCC patients from healthy (AUC = 0.893) and cirrhosis (AUC = 0.892) patients. We identified a serum of miRNA panel that has considerable clinical value in HCC diagnosis.
登录
查看更多内容
影响因子：
13.5
作者：
Collier, J;Sherman, M
通讯作者：
Sherman, M
DOI：
10.1056/nejmoa0901282
发表时间：
2009-10-08
期刊：
The New England journal of medicine
影响因子：
--
作者：
Ji J;Shi J;Budhu A;Yu Z;Forgues M;Roessler S;Ambs S;Chen Y;Meltzer PS;Croce CM;Qin LX;Man K;Lo CM;Lee J;Ng IO;Fan J;Tang ZY;Sun HC;Wang XW
通讯作者：
Wang XW
影响因子：
4
作者：
Kutay, Huban;Bai, Shoumei;Ghoshal, Kalpana
通讯作者：
Ghoshal, Kalpana
循环 microRNA 作为肝硬化的指纹
影响因子：
3.7
作者：
Chen, Yan-Jie;Zhu, Ji-Min;Shen, Xi-Zhong
通讯作者：
Shen, Xi-Zhong
影响因子：
4.1
作者：
Chang, Jinhong;Nicolas, Emmanuelle;Taylor, John M
通讯作者：
Taylor, John M